Little is known of the perinatal consequences of the use of clofazimine (B663, Lamprene) to treat leprosy. Two patients who were treated with the drug throughout pregnancy are presented and the literature is reviewed. Although the 2 current pregnancies ended successfully, 3 neonatal deaths in 15 pregnancies (20%) have been reported. These data suggest that patients taking clofazimine during pregnancy be managed at a perinatal center where adequate neonatal care can be given.
BT - Obstetrics and gynecology C1 - http://www.ncbi.nlm.nih.gov/pubmed/7078842?dopt=Abstract DA - 1982 Jan IS - 1 J2 - Obstet Gynecol LA - eng N2 -Little is known of the perinatal consequences of the use of clofazimine (B663, Lamprene) to treat leprosy. Two patients who were treated with the drug throughout pregnancy are presented and the literature is reviewed. Although the 2 current pregnancies ended successfully, 3 neonatal deaths in 15 pregnancies (20%) have been reported. These data suggest that patients taking clofazimine during pregnancy be managed at a perinatal center where adequate neonatal care can be given.
PY - 1982 SP - 122 EP - 3 T2 - Obstetrics and gynecology TI - Clofazimine in pregnancy complicated by leprosy. VL - 59 SN - 0029-7844 ER -